Question-and-Answer Session
Thank you Mr. Squicciarino. The floor is now open for questions. [Operator Instructions]. Our first question comes from Corey Davis. Go ahead Corey.
Corey Davis - Natexis Bleichroeder
Thanks very much. I had a couple... first how would you describe the pricing dynamics in the thrombin market now that you've got a new competitor there, any pressures left?
Brian A. Markison - President and Chief Executive Officer
Corey, hi it's Brian, thanks for the question. What we are seeing in the thrombin market is a lot of activity, a lot of sales force, competition. But really it's too early to comment at all on pricing based on the market dynamics. We haven't seen anything negative thus far.
Corey Davis - Natexis Bleichroeder
And why so long in between this completion of the Phase III in Corview [ph] in the filing almost a year.
Brian A. Markison - President and Chief Executive Officer
Yes, Corey, I appreciate that. I think when we looked at this program from beginning to end and the need to compare binodenoson or Corview to Adenoscan we were not only comparing it for its ability to cause pharmacologic stress but we are also looking for image concordance between the two agents. And I think the best way to describe this is we have spent a lot of time with our statistical analysis plan and the analysis of the data and that has taken all of the time from now... from then until now.
Corey Davis - Natexis Bleichroeder
Okay. And then last one I guess, I noticed on the court docket on SKELAXIN, that discovery has been delayed and I know Judge Trager is trying to move this along, but is it reasonable to think that you can really get this moving within a few months given the most patent cases take years form discovery to trial?
Brian A. Markison - President and Chief Executive Officer
I don't think it's reasonable, Corey, to expect this to pick up in a couple of months there. Without going into details there is a lot of discovery to do. And the other thing I'd like to reiterate though is we are very, very confident in our intellectual property, in our patents that go out for quite some time.
Corey Davis - Natexis Bleichroeder
I don't suppose you want to comment on the potential for a settlement there on the 800 mix strength.
- To read the full transcript on Seeking Alpha, click here »
